| Literature DB >> 33176589 |
Yongqiang Zhou1, Xiaojun Xiang2, Jianping Xiong2, Changfei Gong2.
Abstract
PURPOSE: The purpose of the present study was first to apply the progressive optimization algorithm based automatic volumetric modulated arc therapy (POA-VMAT) technology to accelerate and improve the radiotherapy of cervicothoracic esophageal cancer (CTEC). We comprehensive analyze the feasibility, normal tissue complication probability (NTCP) and dosimetric results of POA-VMAT, manual based VMAT and step-shoot intensity-modulated radiation therapy (IMRT) plans in the treatment of CTEC.Entities:
Keywords: automatic; cervical-thoracic esophageal cancers; intensity-modulated radiotherapy; normal tissue complication probability; volumetric-modulated arc therapy
Year: 2020 PMID: 33176589 PMCID: PMC7672719 DOI: 10.1177/1533033820973283
Source DB: PubMed Journal: Technol Cancer Res Treat ISSN: 1533-0338
Patient Specifics (n = 60).
| Age (years) | Gender | Performance(WHO) | Pathology | Stage | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median | Range | Male | Female | 0 | 1 | 2 | squamous carcinoma | IIB | IIIA | IIIB |
| 67 | 51-87 | 36 | 24 | 45 | 15 | 0 | 21 | 24 | 15 | |
Figure 1.The transverse, coronal and sagittal dose distributions in one representative patient of for the 3 treatment plans: (A) 7f-IMRT, (B) Single-Arc, (C) Double-Arc, d) POA-VMAT.
Figure 2.Representative normalized, cumulative dose–volume histogram (DVH) comparison in one representative patient of for the 3 treatment plans: (A) 7f-IMRT, (B) Single-Arc, (C) Double-Arc, (D) POA-VMAT.
The Summary of Numeric Analysis From DVH for Target Volumes.
| Parameter | 7f-IMRT | Single-arc | Double-arc | POA-VMAT | P |
|---|---|---|---|---|---|
| CI (%) | 70.4 ± 7.1 | 71.7 ± 8.6 | 72.5 ± 4.6 | 72.1 ± 5.1 | NS |
| PTV (656 ± 112 cm3) | |||||
| Mean (Gy) | 60.8 ± 1.0 | 60.9 ± 1.1 | 60.2 ± 1.0 | 60.3 ± 0.6 | c, e, f |
| HI | 0.17 ± 0.08 | 0.28 ± 0.06 | 0.29 ± 0.06 | 0.28 ± 0.03 | a, b, c |
| D5%-D95% (Gy) | 4.5 ± 1.1 | 3.7 ± 0.8 | 5.1 ± 0.5 | 4.1 ± 0.5 | a, d, f |
| D2% (Gy) | 64.0 ± 1.8 | 63.6 ± 1.5 | 63.5 ± 1.1 | 61.8 ± 0.9 | c, e, f |
| D98% (Gy) | 56.6 ± 0.8 | 56.3 ± 0.6 | 58.0 ± 0.6 | 58.6 ± 0.8 | b, c, d, e |
| V95% (%) | 95.8 ± 3.2 | 95.4 ± 2.3 | 99.4 ± 0.3 | 99.8 ± 0.1 | a, b, c, d, e |
| V107% (%) | 3.0 ± 4.2 | 2.7 ± 2.7 | 1.6 ± 1.3 | 0.3 ± 0.2 | c, e, f* |
Statistically significant differences (p < 0.05) of paired t-test analysis for 4 plans; a: 7f-IMRT vs. Single-Arc; b: 7f-IMRT vs. Double-Arc; c: 7f-IMRT vs. POA-VMAT; d: Single-Arc vs. Double-Arc; e: Single-Arc vs. POA-VMAT; f: Double-Arc vs. POA-VMAT. *: using 2-paired Wilcoxon’s signed ranks test. NS: Not significant.
OARs Dose Calculated From The DVHs.
| Parameter | 7f-IMRT | Single-arc | Double-Arc | POA-VMAT | P | |
|---|---|---|---|---|---|---|
| Lung | Dmean (Gy) | 15.0 ± 2.1 | 15.1 ± 2.0 | 14.5 ± 2.3 | 14.2 ± 2.0 | b, c, d, e |
| V5 Gy (%) | 60.2 ± 13.3 | 60.5 ± 12.9 | 60.2 ± 13.9 | 60.9 ± 14.0 | NS | |
| V10Gy (%) | 50.5 ± 9.0 | 52.8 ± 10.3 | 52.4 ± 12.0 | 52.5 ± 11.5 | a | |
| V20Gy (%) | 30.2 ± 2.5 | 30.3 ± 1.8 | 28.4 ± 2.7 | 25.8 ± 1.6 | b, c, e, f | |
| V30Gy (%) | 16.9 ± 1.6 | 16.1 ± 1.8 | 15.3 ± 1.3 | 14.6 ± 1.6 | a, b, c, d, e | |
| V40Gy (%) | 9.5 ± 2.0 | 9.5 ± 1.8 | 8.8 ± 1.2 | 9.2 ± 1.6 | NS | |
| V50Gy (%) | 5.1 ± 1.4 | 5.0 ± 1.4 | 4.2 ± 1.0 | 4.8 ± 1.1 | b, d | |
| NTCP (Pneumonitis, %) | 8.5 ± 2.5 | 8.7 ± 2.7 | 7.7 ± 2.7 | 7.3 ± 2.7 | b, c, d, e | |
| Spinal Cord | Dmax (Gy) | 42.3 ± 1.2 | 41.4 ± 2.4 | 42.9 ± 1.7 | 40.7 ± 1.8 | NS |
| Heart | Mean (Gy) | 10.4 ± 9.5 | 10.4 ± 9.6 | 10.1 ± 9.3 | 10.1 ± 9.0 | d |
| D35% (Gy) | 9.0 ± 12.8 | 9.0 ± 12.9 | 8.6 ± 11.2 | 8.4 ± 11.0 | NS | |
| Healthy Tissue | Mean (Gy) | 15.9 ± 5.7 | 16.2 ± 5.4 | 15.7 ± 5.0 | 15.7 ± 5.2 | e |
| V5 Gy (%) | 59.5 ± 17.6 | 60.1 ± 16.6 | 62.5 ± 17.4 | 62.7 ± 17.4 | b, c, d, e | |
| V10Gy (%) | 45.2 ± 16.3 | 48.9 ± 15.1 | 50.0 ± 15.6 | 49.4 ± 15.5 | a, b, c | |
| V15Gy (%) | 36.9 ± 13.9 | 40.3 ± 13.4 | 37.5 ± 13.1 | 35.6 ± 13.5 | a, d, e | |
| V20Gy (%) | 28.2 ± 12.4 | 28.4 ± 11.7 | 27.6 ± 11.3 | 26.6 ± 10.6 | NS | |
| Int. dose (×104 Gy cm3) | 20.5 ± 3.3 | 20.8 ± 2.9 | 20.3 ± 3.0 | 20.3 ± 3.3 | d, e |
Statistically significant differences (p < 0.05) of paired t-test analysis for 4 plans; a: 7f-IMRT vs. Single-Arc; b: 7f-IMRT vs. Double-Arc; c: 7f-IMRT vs. POA-VMAT; d: Single-Arc vs. Double-Arc; e: Single-Arc vs. POA-VMAT; f: Double-Arc vs. POA-VMAT. *: using 2-paired Wilcoxon’s signed ranks test. NS: Not significant.
Total MU and Delivery Time.
| Parameter | 7f-IMRT | Single-arc | Double-arc | POA-VMAT | P |
|---|---|---|---|---|---|
| Total MU | 868.2 ± 182.0 | 423.5 ± 52.1 | 870.0 ± 225.3 | 548.8 ± 47.2 | b, c, d, e, f |
| Delivery Time(s) | 198.7 ± 36.5 | 198.0 ± 44.9 | 84.7 ± 10.7 | 113.7 ± 9.4 | b, c, d, e, f |
Statistically significant differences (p < 0.05) of paired t-test analysis for 4 plans; a: 7f-IMRT vs. Single-Arc; b: 7f-IMRT vs. Double-Arc; c: 7f-IMRT vs. POA-VMAT; d: Single-Arc vs. Double-Arc; e: Single-Arc vs. POA-VMAT; f: Double-Arc vs. POA-VMAT. *: using 2-paired Wilcoxon’s signed ranks test. NS: Not significant.